Moderna says FDA delayed RSV vaccine approval to end of May

The FDA has not informed Moderna of any issues related to the vaccine’s safety, efficacy or quality that would prevent its approval, the biotech company said.

Previous post China EV makers under pressure after reports Biden aiming tariffs at the sector
Next post Gold prices soar to best level in weeks as weak jobs data drives rate-cut hopes